Tilray, Inc., a leader in the manufacture, research, and distribution of medical cannabis, has a Agreement reached for the joint marketing of its full-spectrum cannabis extracts in Germany from January 1, 2021.

Hormosan specializes in pain therapy and neurology and belongs to the Lupine Group, an international sales company for innovative drugs and generics. Hormosan will support Tilray in its marketing and sales activities for full spectrum cannabis extracts in Germany. This strategic partnership combines the technical skills of Tilray and Hormosan to strengthen Tilray's presence in the German market.

Tilray launched its full-spectrum cannabis extracts in October 2017 and last expanded its product range in May 2020. The product range includes an extract with a balanced ratio of THC and CBD, an extract with high CBD and low THC content, and a pure THC Full spectrum extract. According to legal regulations, the use of full-spectrum cannabis extracts is not restricted to a specific indication, and the treating physician can decide at his own discretion whether a treatment is suitable. The Tilray extracts are used for chronic pain, spasticity, insomnia and a variety of other indications.

"With Hormosan we have found a partner who has outstanding expertise and excellent contacts in the field of pain treatment and neurology and will thus significantly increase the visibility of the full spectrum cannabis extracts from Tilray in the future," says Sascha Mielcarek, Managing Director Europe at Tilray . "This cooperation gives doctors and patients even easier access to our medical cannabis extracts and at the same time supports our goal of improving patient care with the help of medical cannabis."

“As one of the leading providers of full-spectrum cannabis extracts, Tilray is a perfect partner for Hormosan. As part of the joint marketing of medical cannabis extracts, we are expanding our competencies and our therapeutic range in the field of pain treatment and neurology, ”comments Anjan Selz, Managing Director, Hormosan. "The complementarity of medical cannabis with existing therapies offers doctors and their patients promising opportunities."

About Tilray®

Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids. The company currently cares for more than 25,000 patients and consumers in 15 countries on five continents. More information is available on the Internet at tilray.de.

About hormosan

Hormosan Pharma GmbH was founded in Germany more than 50 years ago and has been part of the international Lupine Group since 2008. With innovative and generic active ingredients, Hormosan supports the best available treatment in the areas of neurology, pain management, and sexual health and HIV. The focus is on the unmet medical needs of patients, the improvement of their quality of life and the availability of alternative treatment options. Further information is available at www.hormosan.de .

The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. You should therefore compare translations with the original language version of the publication.

Contacts
National press
contact 3K Agency for Communication GmbH
Dr. Anika Burkard | Tamara Wemmer
Feldbergstrasse 35
60323 Frankfurt am Main
+49 (0) 69 97 17 11-0
presse@3k-kommunikation.de
www.3k-kommunikation.de

Tilray national company
contact Tilray Deutschland GmbH
Maike Gerlach
Friedrichstr. 153A
10117 Berlin
+ 49 (0) 30 629 33 050
presse@tilray.de
www.tilray.de

Hormosan national company contact
Hormosan Pharma GmbH
Anjan Selz
Hanauer Landstrasse 139-143
60314 Frankfurt aM
+49 (0) 69 - 47 873 44
info@hormosan.de
www.hormosan.de

 

Source: businesswire.com

Report Abuse